pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Akeega
drug
save

(abiraterone acetate + niraparib)

Marketedupdated 3mo ago
by $JNJ JOHNSON & JOHNSON
Approved
community read0 votes

🐶 often sniffed alongside

top 6
  • drugAKEEGA4 co-mentions · 2 sources
  • tagApproval4 co-mentions · 2 sources
  • drugabiraterone acetate2 co-mentions · 2 sources
  • companyJanssen Biotech Inc2 co-mentions · 2 sources
  • tagSmall Molecule2 co-mentions · 2 sources
  • drugYonsa2 co-mentions · 2 sources

all catalysts(2)

approval · 2
Aug 11, 2023
approval
3y ago
AKEEGA (ABIRATERONE ACETATE) — FDA approval
(abiraterone acetate + niraparib)
→
Dec 12, 2025
approval
8mo ago
AKEEGA (ABIRATERONE ACETATE) — FDA approval
(abiraterone acetate + niraparib)
→

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 12, 2027
361 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (26)

  • Mar 27, 2038compositionUS 11091459
  • Mar 27, 2038compositionUS 11091459
  • Mar 27, 2038compositionUS 11673877
  • Mar 27, 2038compositionUS 11673877
  • Jul 28, 2037method-of-use (U-4368)US 11207311
  • Jul 28, 2037method-of-use (U-4368)US 11207311
  • Jul 28, 2037method-of-use (U-2830)US 11986468
  • Jul 28, 2037method-of-use (U-2830)US 11986468
  • Jul 28, 2037method-of-use (U-2830)US 11986469
  • Jul 28, 2037method-of-use (U-2830)US 11986469
  • Jul 28, 2037method-of-use (U-4368)US 11986470
  • Jul 28, 2037method-of-use (U-4368)US 11986470
  • Jul 28, 2037method-of-use (U-2830)US 11992486
  • Jul 28, 2037method-of-use (U-2830)US 11992486
  • Jul 28, 2037method-of-use (U-2830)US 12383543
  • Jul 28, 2037method-of-use (U-2830)US 12383543
  • Aug 4, 2031method-of-use (U-4368)US 88595625.0y
  • Aug 4, 2031method-of-use (U-4368)US 88595625.0y
  • Mar 27, 2031compositionUS 80716234.6y
  • Mar 27, 2031compositionUS 80716234.6y
  • Apr 24, 2029compositionUS 84361852.7y
  • Apr 24, 2029compositionUS 84361852.7y
  • Aug 12, 2027method-of-use (U-4368)US 8071579361d
  • Aug 12, 2027method-of-use (U-4368)US 8071579361d
  • Aug 12, 2027method-of-use (U-4368)US 8143241361d
  • Aug 12, 2027method-of-use (U-4368)US 8143241361d

FDA exclusivities (4)

  • Dec 12, 2028I-980Indication (3y)2.3y
  • Dec 12, 2028I-980Indication (3y)2.3y
  • Aug 11, 2026NPNP
  • Aug 11, 2026NPNP

News(1)

  • GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
    We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
    onclive · 3mo ago
brand
Akeega
generic
(abiraterone acetate + niraparib)
indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 17m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?